ABCL vs CRL: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CRL is the larger of the two ($15.09B market cap): the incumbent the market prices for continued execution (24.28x forward earnings, beta 1.34). ABCL is the smaller challenger ($3.26B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, ABCL fits: analysts expect its revenue to rise 14% next year, against 3% for CRL. If you believe in profit, CRL fits: it is expected to make money next year (24.28x forward earnings), while ABCL is still expected to post a loss.
ABCL vs CRL: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABCL | CRL | What it tells you |
|---|---|---|---|
| Market cap | $3.26B | $15.09B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -14.17 | 24.28 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.59 | 1.34 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 59% of range | 72% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.06 | 4.67 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how ABCL and CRL affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABCL and CRL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABCL and CRL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AbCellera Biologics (ABCL) do?
AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Since 2023 it has deliberately scaled back partnership volume to redirect resources into its own internal pipeline, moving from a services-and-royalties model toward being a clinical-stage drug developer that captures more of the upside if its molecules succeed.
What does Charles River Laboratories International (CRL) do?
Charles River Laboratories International, Inc. is a leading global contract research organization that helps pharmaceutical and biotech companies discover, develop, and safely test new drugs. It runs three reporting segments: Research Models and Services (RMS), which breeds and supplies purpose-bred lab animals and related services; Discovery and Safety Assessment (DSA), its largest segment, which runs toxicology and safety-testing studies that drugs must pass before human trials; and Manufacturing Solutions, which provides quality-control testing for biologics, cell and gene therapies, and other products. Charles River says it has supported a large majority of the drugs approved by the FDA in recent years, which underlines how embedded it is in the industry's R&D pipeline.
ABCL vs CRL: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- ABCL drivers: ABCL-635 heads toward late-stage trials; Deep cash runway.
- CRL drivers: Biopharma R&D demand recovery; Activist-driven strategic review.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. For CRL, the central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending.
ABCL or CRL: which should you pick?
If the story you believe is ABCL's (ABCL-635 heads toward late-stage trials), ABCL is the more direct way to own it; if it is CRL's (Biopharma R&D demand recovery), CRL is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABCL and CRL guides.
ABCL vs CRL: the full fundamentals
ABCL. AbCellera has no P/E because it is unprofitable, so investors typically frame it on cash-versus-market-cap and pipeline optionality. After the offering, cash covers about a quarter of the roughly $3.2B market value, up from about a seventh in October, as the share price fell and the cash pile grew, so most of the price still reflects expectations for ABCL-635. Analysts remain upbeat, with an average target near $18.69 across 13 analysts and a strong buy consensus.
CRL. Thin trailing GAAP earnings after restructuring, impairment and divestiture effects make the trailing P/E meaningless, so CRL is valued on adjusted earnings: about 24 times forward estimates, with analysts expecting 2026 EPS near $11.47 and about $12.97 in 2027. That multiple has expanded with the stock's 2026 rally, so it now assumes the margin gains and the bookings recovery hold. Fourteen covering analysts carry a buy consensus with a mean target near $351; figures are approximate as of November 20, 2026.
Headline figures (approximate, November 2026): ABCL shows market cap ~$3.2B, share price (nov 20, 2026) ~$9.93, revenue (ttm) ~$68M, revenue (q3 2026) ~$10.6M (up ~19% yr-ago); CRL shows revenue (ttm) ~$4.0B; Q3 2026 ~$983M, down ~2.2% YoY, organic up ~4.7%, adjusted eps (q3 2026) ~$3.09 vs ~$2.98 consensus, net income (ttm) ~$40M GAAP, after Q3 GAAP net income of ~$333M, dsa net bookings (q3 2026) ~$652M, up ~32% YoY; book-to-bill ~1.09x; backlog ~$2.03B.
The bottom line: ABCL vs CRL
ABCL and CRL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ABCL and CRL exposure against your real portfolio. It is not an investment adviser.
Wondering how ABCL or CRL fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about AbCellera Biologics
Ask Walnut's AI anything about ABCL and see how it fits what you own.
FAQ
What is the difference between ABCL and CRL?
+
AbCellera Biologics (Nasdaq: ABCL) built an AI-assisted, single-cell antibody-discovery platform (spun out of the University of British Columbia) that it originally rented to pharma partners such as Eli Lilly, Regeneron, AbbVie and Biogen in exchange for research fees, milestones and downstream royalties. Charles River Laboratories International, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABCL or CRL the better stock?
+
Neither is universally better. CRL is the larger incumbent; ABCL is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABCL or CRL?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABCL and CRL?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABCL vs CRL?
+
ABCL: AbCellera is unprofitable and burning cash at the operating level, posting a net loss of about $41M in Q3 2026 on about $10.6M of quarterly revenue, so the market value rests on future clinical success, not current earnings. After a roughly 190% gain in 2026 the stock carries high expectations for ABCL-635, and with ABCL-575 shelved after Phase 1 the company is closer to a single-asset story: weaker late-stage data, safety findings (liver monitoring is a known issue in the NK3R class), or competition from approved non-hormonal therapies could sharply reset the valuation. The 2026 offering already diluted holders by about 8% in share count, and late-stage trials are expensive. Platform revenue has fallen far from its pandemic-era peak (when Lilly antibody royalties were large), is lumpy and partner-dependent, and the number of partner-led programs fell to 34 from 44 this year. Drug development carries the usual risks of trial failure, regulatory delay and competition in crowded indications, and while the cash runway is long, sustained losses (analysts expect about -$0.61 EPS for 2026 and -$0.70 for 2027) could eventually require more financing. CRL: The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. Client concentration and the lumpiness of large study bookings add volatility to any given quarter. The activist strategic review is a double-edged sword: it could unlock value, but the outcome, timing, and any divestitures are uncertain and may disappoint. Regulatory and reputational scrutiny around animal research, plus a long-term industry shift toward non-animal testing methods, could pressure the RMS segment over time. The company also carries debt from past acquisitions, so a prolonged demand slump would weigh on cash flow and flexibility. Competition from other large CROs on price and capacity is persistent. After a rally of about 55% in 2026, the shares trade near 24 times forward earnings, so a stall in the margin story would meet higher expectations than a year ago; the stock already fell about 9% in the month to November 20, 2026 from its high. Total debt sits near $2.85 billion against about $200 million of cash, with net leverage about 2.3x, and operating cash flow for the first nine months of 2026 was lower than a year earlier.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABCL or CRL; figures are approximate and dated (as of November 2026). Verify current data before investing.